Search Results - "Squamous Cell Carcinoma of Head and Neck/secondary"
-
1
Authors: et al.
Contributors: et al.
Source: International journal of radiation oncology, biology, physics, vol. 121, no. 5, pp. 1194-1206
Subject Terms: Humans, Quality of Life, Radiosurgery/methods, Radiosurgery/mortality, Male, Female, Middle Aged, Head and Neck Neoplasms/mortality, Head and Neck Neoplasms/pathology, Head and Neck Neoplasms/therapy, Head and Neck Neoplasms/radiotherapy, Head and Neck Neoplasms/drug therapy, Aged, Neoplasm Metastasis, Cetuximab/administration & dosage, Cetuximab/therapeutic use, Fluorouracil/administration & dosage, Squamous Cell Carcinoma of Head and Neck/mortality, Squamous Cell Carcinoma of Head and Neck/therapy, Squamous Cell Carcinoma of Head and Neck/secondary, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Adult, Survival Rate
File Description: application/pdf
-
2
Authors: et al.
Contributors: et al.
Source: Cancer Res Treat
Subject Terms: Adult, Male, Immune Checkpoint Inhibitors / therapeutic use, Neutrophils, Clinical Decision-Making, Drug Resistance, Squamous Cell Carcinoma of Head and Neck / drug therapy, Immune check point, Head and neck neoplasms, 03 medical and health sciences, 0302 clinical medicine, Sum of target lesions, 80 and over, Humans, Lymphocyte Count, Lymphocytes, 10. No inequality, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Aged, 80 and over, Immune Checkpoint Inhibitors / pharmacology, Squamous Cell Carcinoma of Head and Neck / blood, Head and Neck Neoplasms / mortality, Patient Selection, Local / drug therapy, Platinum refractory, Local / blood, Head and Neck Neoplasms / pathology, Head and Neck Neoplasms / drug therapy, Squamous Cell Carcinoma of Head and Neck / secondary, Middle Aged, Prognosis, Progression-Free Survival, 3. Good health, Neoplasm Recurrence, Drug Resistance, Neoplasm, Head and Neck Neoplasms, Risk Assessment / methods, Neoplasm, Head and Neck Neoplasms / blood, Original Article, Female, Neoplasm Recurrence, Local, Squamous Cell Carcinoma of Head and Neck / mortality, Local / mortality, Biomarkers, Follow-Up Studies
Access URL: http://www.e-crt.org/upload/pdf/crt-2020-824.pdf
https://pubmed.ncbi.nlm.nih.gov/33285051
https://www.ncbi.nlm.nih.gov/pubmed/33285051
http://www.e-crt.org/upload/pdf/crt-2020-824.pdf
https://www.e-crt.org/journal/view.php?number=3184
https://pubmed.ncbi.nlm.nih.gov/33285051/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291197 -
3
Authors: et al.
Source: J Cancer Res Clin Oncol
Subject Terms: Adult, Aged, 80 and over, Male, Squamous Cell Carcinoma of Head and Neck, Original Article – Clinical Oncology, Palliative immunotherapy, Aged, 80 and over [MeSH], Aged [MeSH], Palliative chemotherapy, Squamous Cell Carcinoma of Head and Neck/epidemiology [MeSH], Metastatic disease, Neoplasm Recurrence, Local/pathology [MeSH], Germany/epidemiology [MeSH], Male [MeSH], Carcinoma, Head and Neck Neoplasms/epidemiology [MeSH], Recurrent disease, Female [MeSH], Follow-Up Studies [MeSH], Adult [MeSH], Head and neck, Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Squamous Cell Carcinoma of Head and Neck/drug therapy [MeSH], Squamous Cell Carcinoma of Head and Neck/secondary [MeSH], Head and Neck Neoplasms/drug therapy [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Survival Rate [MeSH], Health Services Research/statistics, Prognosis [MeSH], Neoplasm Recurrence, Local/drug therapy [MeSH], Neoplasm Recurrence, Local/epidemiology [MeSH], Head and Neck Neoplasms/pathology [MeSH], Middle Aged, Prognosis, 3. Good health, Survival Rate, 03 medical and health sciences, 0302 clinical medicine, Head and Neck Neoplasms, Germany, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Health Services Research, Neoplasm Recurrence, Local, Aged, Follow-Up Studies, Retrospective Studies
Access URL: https://link.springer.com/content/pdf/10.1007/s00432-021-03535-4.pdf
https://pubmed.ncbi.nlm.nih.gov/33517469
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310840
https://europepmc.org/article/MED/33517469
https://www.ncbi.nlm.nih.gov/pubmed/33517469
https://pubmed.ncbi.nlm.nih.gov/33517469/
https://link.springer.com/article/10.1007/s00432-021-03535-4
https://link.springer.com/content/pdf/10.1007/s00432-021-03535-4.pdf
https://repository.publisso.de/resource/frl:6449922 -
4
Authors: et al.
Contributors: et al.
Subject Terms: Humans, Squamous Cell Carcinoma of Head and Neck/pathology, Squamous Cell Carcinoma of Head and Neck/mortality, Squamous Cell Carcinoma of Head and Neck/secondary, Squamous Cell Carcinoma of Head and Neck/therapy, Neoplasm Recurrence, Local/pathology, Consensus, Head and Neck Neoplasms/pathology, Head and Neck Neoplasms/mortality, Head and Neck Neoplasms/therapy, Endpoint Determination/standards, Clinical Trials, Phase III as Topic, Neoplasm Metastasis
Relation: The Lancet Oncology; https://iris.unil.ch/handle/iris/215063; serval:BIB_AF66A4CF28EE; 001260855700001
Availability: https://iris.unil.ch/handle/iris/215063
https://doi.org/10.1016/S1470-2045(24)00068-8 -
5
Authors: et al.
Contributors: et al.
Source: The Lancet, Vol. 393, No 10167 (2019) pp. 156-167
Lancet, Vol. 393, no. 10167, p. 156-167 (2019)Subject Terms: Neoplasm recurrence, Male, Kaplan-Meier estimate, Antineoplastic combined chemotherapy protocols - administration & dosage, Cetuximab - adverse effects, Head and neck neoplasms - drug therapy, monoclonal, Cetuximab, Docetaxel - administration & dosage, Docetaxel, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized, Antibodies, Squamous cell carcinoma of head and neck - drug therapy, Drug Administration Schedule, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Methotrexate - administration & dosage, Middle aged, Humanized, humanized - administration & dosage, Aged, ddc:616, Disease progression, Squamous Cell Carcinoma of Head and Neck, Drug administration schedule, Head and neck neoplasms - pathology, Squamous cell carcinoma of head and neck - pathology, humanized - therapeutic use, Middle Aged, Squamous cell carcinoma of head and neck - secondary, 3. Good health, Neoplasm Recurrence, Methotrexate, Local, Antineoplastic combined chemotherapy protocols - therapeutic use, local - drug therapy, Antineoplastic combined chemotherapy protocols - adverse effects, Head and Neck Neoplasms, KEYNOTE-040 investigators, Disease Progression, Methotrexate - adverse effects, Female, Neoplasm Recurrence, Local, Cetuximab - administration & dosage, Docetaxel - adverse effects
File Description: application/pdf; Print-Electronic
Access URL: https://pubmed.ncbi.nlm.nih.gov/30509740
https://www.ncbi.nlm.nih.gov/pubmed/30509740
https://europepmc.org/article/MED/30509740
https://koreauniv.pure.elsevier.com/en/publications/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recu
https://www.sciencedirect.com/science/article/abs/pii/S0140673618319998
https://pubmed.ncbi.nlm.nih.gov/30509740/
https://jhu.pure.elsevier.com/en/publications/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recu
https://archive-ouverte.unige.ch/unige:155811
https://hdl.handle.net/2078.1/212774 -
6
Contributors: et al.
Subject Terms: Animals, Antineoplastic Agents / adverse effects, Antineoplastic Agents / therapeutic use, Blood Platelets / drug effects, Blood Platelets / metabolism, Cell Movement / drug effects, Humans, Lectins, C-Type / antagonists & inhibitors, C-Type / metabolism, Membrane Glycoproteins / antagonists & inhibitors, Membrane Glycoproteins / metabolism, Molecular Targeted Therapy, Mouth Neoplasms / blood, Mouth Neoplasms / drug therapy, Mouth Neoplasms / pathology, Neoplasm Invasiveness, Platelet Aggregation Inhibitors / adverse effects, Platelet Aggregation Inhibitors / therapeutic use, Signal Transduction, Squamous Cell Carcinoma of Head and Neck / blood, Squamous Cell Carcinoma of Head and Neck / drug therapy, Squamous Cell Carcinoma of Head and Neck / secondary, Tumor Microenvironment, CLEC2, PDPN, ezrin/radixin/moesin (ERM), oral cancer, platelets, tumor cell-induced platelet aggregation (TCIPA)
File Description: application/pdf
Relation: FRONTIERS IN IMMUNOLOGY; J03075; https://ir.ymlib.yonsei.ac.kr/handle/22282913/187699; T202125135
-
7
Authors: et al.
Subject Terms: Benchmarking, France, Head and Neck Neoplasms/pathology, Head and Neck Neoplasms/radiotherapy, Humans, Neoplasm Metastasis/radiotherapy, Organs at Risk, Pharyngeal Neoplasms/pathology, Pharyngeal Neoplasms/radiotherapy, Quality Assurance, Health Care, Radiometry, Radiosurgery/instrumentation, Radiosurgery/methods, Radiosurgery/standards, Radiotherapy Dosage, Squamous Cell Carcinoma of Head and Neck/radiotherapy, Squamous Cell Carcinoma of Head and Neck/secondary, Assurance qualité, Benchmark case, Cancer, Clinical trial, Deviation, Déviation, Essai clinique, Head and neck, ORL, Radiothérapie stéréotaxique, Stereotactic radiotherapy
Relation: Cancer/Radiothérapie; https://iris.unil.ch/handle/iris/200883; serval:BIB_770454ACEC36; 000720931300002
Nájsť tento článok vo Web of Science 
Full Text 
Full Text Finder